DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation

B Dhakal; A D'Souza; M Pasquini; W Saber; T S Fenske; R B Moss; W R Drobyski; P Hari; M Z Abidi

doi:10.1155/2016/8503275

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation

Case Rep Med. 2016:2016:8503275. doi: 10.1155/2016/8503275. Epub 2016 Jan 28.

Authors

B Dhakal¹, A D'Souza¹, M Pasquini¹, W Saber¹, T S Fenske¹, R B Moss², W R Drobyski¹, P Hari¹, M Z Abidi³

Affiliations

¹ Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
² Ansun BioPharma, San Diego, CA 92121, USA.
³ Division of Infectious Disease, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Abstract

Parainfluenza virus (PIV) may cause life-threatening pneumonia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Currently, there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, for treatment of PIV type 3 pneumonia in two allogeneic hematopoietic SCT recipients with respiratory failure.

Grants and funding

U24 CA076518/CA/NCI NIH HHS/United States